Physician profile
Vinod Gupta
NPI 1407902331
$5,533.06
in general payments reported to CMS, 2019-2025
22 companies · $780 in 2025
The $780 reported for 2025 was more than what 85% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $913 · 2020: $562 · 2021: $644 · 2022: $846 · 2023: $760 · 2024: $1,028 · 2025: $780.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,568.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,568.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,448.16 | 2019-2025 | Repatha, Repatha |
| Shockwave Medical, INC | $278.89 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Janssen Pharmaceuticals, INC | $273.59 | 2019-2023 | Xarelto |
| Lundbeck LLC | $210.47 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $198.47 | 2019-2025 | Camzyos, Eliquis |
| Abiomed | $192.11 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $170.83 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $125.17 | 2021-2023 | Verquvo |
| Novo Nordisk INC | $106.72 | 2024-2025 | |
| Pfizer INC. | $85.15 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $84.86 | 2022-2025 | |
| Scpharmaceuticals INC. | $66.22 | 2023-2025 | |
| Boston Scientific Corporation | $45.46 | 2019 | |
| Alnylam Pharmaceuticals INC. | $44.26 | 2025 | Amvuttra |
| Astrazeneca Pharmaceuticals Lp | $39.52 | 2019-2025 | Farxiga |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.17 | 2025 | Jardiance |
| Kiniksa Pharmaceuticals International, Plc | $31.26 | 2024 | Arcalyst |
| Abbott Laboratories | $29.39 | 2019 | |
| Penumbra, INC. | $17.50 | 2022 | |
| Arbor Pharmaceuticals, INC. | $17.09 | 2021 | |
| Astellas Pharma US INC | $16.75 | 2019 | |
| Baxter Healthcare | $16.02 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinod Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.